Journal of the American Academy of Dermatology
Comment on 'Efficacy, safety, and B-cell depletion capacity of 3 rituximab dosing regimens in the treatment of moderate-to-severe pemphigus vulgaris and pemphigus foliaceus: A 52-week clinical trial'.
Cheng Xue
Published: 202610.1016/j.jaad.2025.10.170
No abstract available for this study.